Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Sees Large Increase in Short Interest

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 20,200 shares, an increase of 71.2% from the September 15th total of 11,800 shares. Based on an average daily volume of 517,400 shares, the days-to-cover ratio is currently 0.0 days.

Scinai Immunotherapeutics Stock Performance

SCNI opened at $3.80 on Monday. Scinai Immunotherapeutics has a one year low of $2.23 and a one year high of $8.92. The company has a market cap of $1.76 million, a price-to-earnings ratio of -0.01 and a beta of 2.47. The business’s fifty day moving average is $3.72 and its two-hundred day moving average is $3.98.

Scinai Immunotherapeutics (NASDAQ:SCNI) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($3.57) EPS for the quarter. The company had revenue of $0.28 million for the quarter.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.